# Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder

> **NCT02191397** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 534 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Bupropion
- **DRUG:** Bupropion Matching Placebo
- **DRUG:** Escitalopram
- **DRUG:** Escitalopram Matching Placebo

## Key facts

- **NCT ID:** NCT02191397
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-10
- **Primary completion:** 2016-10-10
- **Final completion:** 2016-10-25
- **Target enrollment:** 534 (ACTUAL)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02191397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02191397, "Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02191397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*